NCT01756924View on ClinicalTrials.gov

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Prosthetic Joint Infections of HipProsthetic Joint Infections of KneeInfected Spacers
Interventions
DRUG

CEM-102

DRUG

IV or Oral standard of care antibiotics

DRUG

Rifampin

Trial Locations (13)

13507

Syracuse

15232

Pittsburgh

19107

Philadelphia

21215

Baltimore

21218

Baltimore

27710

Durham

29425

Charleston

31419

Savannah

33321

Tamarac

34232

Sarasota

77030

Houston

77043

Houston

02215

Boston

Sponsors

Lead Sponsor

Arrevus Inc.
All Listed Sponsors
lead

Arrevus Inc.

INDUSTRY

NCT01756924 - Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection | Biotech Hunter | Biotech Hunter